Antimicrobial therapy in community-acquired pneumonia among emergency patients in a university hospital in Japan

Journal of Infection and Chemotherapy

Volumn 10, Issue 6, 2004, Pages 352-358

  Kawai, Shin ^a   Ochi, Masaru ^a   Nakagawa, Tomoyuki ^a   Goto, Hajime ^a  

^a KYORIN UNIVERSITY   (Japan)

Author keywords

Antimicrobial agent; Community acquired pneumonia; Guideline

Indexed keywords

ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEPHALOSPORIN; CLINDAMYCIN; MINOCYCLINE; PENICILLIN G; PIPERACILLIN; SULTAMICILLIN;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; ELDERLY CARE; FEMALE; HAEMOPHILUS INFLUENZAE; HOSPITAL ADMISSION; HUMAN; JAPAN; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYCOPLASMA PNEUMONIA; PROGNOSIS; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT DISEASE; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIA; TIME SERIES ANALYSIS; UNIVERSITY HOSPITAL;

EID: 12444278910     PISSN: 1341321X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10156-004-0350-2     Document Type: Article

References (14)

1. Yanagihara K, Kohno S, Matsusima T. Japanese guidelines for the management of community-acquired pneumonia. Int J Antimicrob Agents 2001;18(Suppl 1):S45-8.
2. Niederman MS, Bass JB Jr, Cambell GD, Fein AM, Grossman RF, Mandell LA, et al. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association. Am Rev Respir Dis 1993;148:1418-26.
3. Bartlett JG, Breiman RF, Mandell LA, File TM Jr. Community-acquired pneumonia in adults: guidelines for management. Clin Infect Dis 1998;26:811-38.
4. Ishida T, Hashimoto T, Arita M, Ito I, Osawa M. Etiology of community-acquired pneumonia in hospitalized patients: a 3-year prospective study in Japan. Chest 1998;114:1588-93.
5. Ruiz M, Ewig S, Torres A, Arancibia F, Marco F, Mensa J, et al. Severe community-acquired pneumonia. Risk factors and follow-up epidemiology. Am J Respir Crit Care Med 1999;160:923-9.
6. Brown PD, Lerner SA. Community-acquired pneumonia. Lancet 1998;352:1295-302.
7. Sanyal S, Smith PR, Saha AC, Gupta S, Berkowitz L, Homel P. Initial microbiologic studies did not affect outcome in adults hospitalized with community-acquired pneumonia. Am J Respir Crit Care Med 1999;160:346-8.
8. Guglielmo L, Leone R. Aetiology and therapy of community-acquired pneumonia: a hospital study in northern Italy. Veneto Pneumonia Research Group. Eur J Clin Pharmacol 1997;51:437-43.
9. Moola S, Hagberg L, Churchyard GA, Dylewski JS, Sedani S, Staley H. A multicenter study of grepafloxacin and clarithromycin in the treatment of patients with community-acquired pneumonia. Chest 1999;116:974-83.
10. Yano H, Kuga A, Okamoto R, Kitasato H, Kobayashi T, Inoue M. Plasmid-encoded metallo-β-lactamase (IMP-6) conferring resistance to carbapenems, especially meropenem. Antimicrob Agents Chemother 2001;45:1343-8.
11. Marik PE. The clinical features of severe community-acquired pneumonia presenting as septic shock. Norasept II Study Investigators. J Crit Care 2000;15:85-90.
12. Wunderink RG, Waterer GW. Severe community-acquired pneumonia: the need to customize empiric therapy. Chest 2001;120:1053-5.
13. Anstey NM, Currie BJ, Withnall. Community-acquired Acinetobacter pneumonia in the Northern Territory of Australia. Clin Infect Dis 1992;14:83-91.
14. Perlino CA, Rimland D. Alcoholism, leukopenia, and pneumococcal sepsis. Am Rev Respir Dis 1985;132:757-60.